Healthcare / BiotechnologyNasdaqGS
$1.43
-0.04 (-2.72%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-81.9M · quality 69.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$99M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-60.8%
↓Gross Margin
N/A
•Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.91x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-89.7M · FCF $-81.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Net Income | $-89.7M | $-89.7M | $-90.0M | $-78.6M | $-69.1M | $-27.3M |
| EBITDA | $-88.5M | $-88.5M | $-92.5M | $-83.9M | $-67.8M | $-26.9M |
| EPS | -2.12 | -2.12 | -2.85 | -3.30 | -2.91 | -30.27 |
| Balance Sheet | ||||||
| Debt/Equity | 0.12 | 0.12 | 0.16 | 0.19 | 0.14 | — |
| Current Ratio | 14.98 | 14.98 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-81.9M | $-81.9M | $-82.9M | $-71.6M | $-63.0M | $-23.1M |
| Returns | ||||||
| ROE | -60.8% | -60.8% | -75.9% | -72.5% | -38.5% | 85.0% |
| Valuation | ||||||
| P/B | 0.41 | 0.41 | 1.02 | 1.69 | 1.99 | — |
| Growth & Yield | ||||||
| EPS Growth | 25.6% | 25.6% | 13.6% | -13.2% | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-0.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.85 → -2.12
Residual
-0.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.